Keros will be down to 85 full-time employees after the layoffs and expects to generate annualized savings of $17 million.

Keros Therapeutics is ending development of a phase 2 candidate designed to treat high blood pressure in the lungs, a move ...

Keros Therapeutics is slashing its workforce by 45% as part of a restructuring following a decision by the clinical-stage biopharmaceutical company to end development of its cibotercept product ...

Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE ...

John Mauceri, an award-winning music conductor, author, and recording artist, is celebrating his return to the stage in ...

Medical pros revisit the 150-year history of coffee enemas to weigh their potential benefits and hidden dangers.

Discontinues Development of Cibotercept in PAH Announces Corporate Restructuring to Align Operations with Ongoing Strategic Priorities LEXINGTON, Mass., May 29, 2025 (GLOBE NEWSWIRE) -- Keros Therapeu ...

Objective Biochemical analysis of pericardial fluid (PF) is commonly performed for the initial ... normal composition of PF in candidates for cardiac surgery. Methods Cohort study with analysis of PF ...

We also placed a fluid-filled catheter in the carotid artery ... We did not randomize the order of the study because it was not feasible to adequately reconstruct the pericardium after widely incising ...

Circulating tumor DNA and late recurrence in high-risk, hormone receptor-positive, HER2-negative breast cancer: An updated analysis of the CHiRP study. ESCAT classification of pathogenic variants ...

Researchers used PET/MRI to detect otherwise invisible inflammation. Less clear is how this might influence patient care.

Participants in the highest BGAT quartile of this study had a hazard ratio for VTE risk of 2.12 compared with those in the lowest BGAT quartile after adjusting for age and sex characteristics.